By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to ...

By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Momentum Continues with Presentations at ASCO and ESMO Imunon, Inc. (NASDAQ:IMNN) has a number of important ...

IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting. Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian ...

Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with ...

Imunon, Inc. (NASDAQ:IMNN) Q4 2024 Results Conference Call February 26, 2025 11:00 AM ETCompany ParticipantsPeter Vozzo - ICR Healthcare, IRStacy Lindborg - ...

Data reinforce dose-dependent mechanism with IMNN-001 100mg/m2 dose associated with 20% increase in IL-12 levels compared to 79mg/m2 doseResults f ...

Based on analysts offering 12 month price targets for IMNN in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Sign in to your ...

LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an ...

Imunon, Inc. (NASDAQ:IMNN) Q3 2024 Earnings Conference Call November 7, 2024 11:00 AM ETCompany ParticipantsKim Golodetz - Alliance Advisors IRStacy ...